Evidence map›Paper›PMID 30660595›Full record

ArticleThe lancet. Diabetes & endocrinology2019

Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study.

Frederic Castinetti, Steven G Waguespack, Andreas Machens, Shinya Uchino, Kornelia Hasse-Lazar, Gabriella Sanso, Tobias Else, Sarka Dvorakova, Xiao Ping Qi, Rossella Elisei and 56 more

Erratum issuedOpen access · bronzeAbstract readMulticenter Study
In one paragraph

Article in The lancet. Diabetes & endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 62 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 4 pooled it
11.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 4 syntheses or guidelines pooled it, 146 citations in OpenAlex.

  1. Clinical Outcomes of the GermlineMedicina (Kaunas, Lithuania) · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Guideline
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Observational
  12. Prevalence and genetics of "de novo" MEN2 syndromes.The Journal of clinical endocrinology and metabolism · 2025
    Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma.The Journal of clinical endocrinology and metabolism · 2025
    Article
  18. Cancers · 2025
    Article
  19. Surgical Treatment of Medullary Thyroid Cancer.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2025
    Review
  20. Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

66 authors at 20 institutions in 21 countries.

Frederic CastinettiAix-Marseille Université, Institut National de la Santé et de la Recherche Médicale, Marseille Medical Genetics, Marseille, France; Assistance Publique-Hôpitaux de Marseille, Department of Endocrinology, Hôpital de la Conception, Centre de Référence des Maladies Rares de l'hypophyse, Marseille, France. Electronic address: frederic.castinetti@ap-hm.fr.
Steven G WaguespackDepartment of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Andreas MachensDepartment of General, Visceral and Vascular Surgery, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Shinya UchinoNoguchi Thyroid Clinic and Hospital Foundation, Beppu, Japan.
Kornelia Hasse-LazarDepartment of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Gliwice, Poland.
Gabriella SansoCentro de Investigaciones Endocrinológicas, "Dr César Bergadá", Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina.
Tobias ElseDivision of Metabolism, Endocrinology, & Diabetes, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA.
Sarka DvorakovaDepartment of Molecular Endocrinology, Institute of Endocrinology, Prague, Czech Republic.
Xiao Ping QiDepartments of Oncologic and Urologic Surgery, The 117th People's Liberation Army Hospital, People's Liberation Army Hangzhou Clinical College, Anhui Medical University, Hangzhou, China.
Rossella EliseiDepartment of Endocrinology, University Hospital, Pisa, Italy.
Ana Luisa MaiaThyroid Section, Endocrinology Division, Hospital de Cliínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
John GlodPediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Delmar Muniz LourençoEndocrine Genetics Unit, Endocrinology Division, Hospital das Clínicas, University of São Paulo School of Medicine, São Paulo, Brazil; Endocrine Oncology Division, Institute of Cancer of the State of São Paulo, Faculty of Medicine of the University of São Paulo, São Paulo, Brazil.
Nuria ValdesDepartment of Endocrinology and Nutrition, Hospital Universitario Central de Asturias, Oviedo, Spain; Unit of Endocrinology, Nutrition, Diabetes and Obesity, Institute of Sanitary Research of Asturias, Oviedo, Spain.
Jes MathiesenDepartment of Otorhinolaryngology, Head and Neck Surgery and Audiology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Nelson WohllkEndocrine Section, Universidad de Chile, Hospital del Salvador, Santiago de Chile, Santiago, Chile.
Tushar R BandgarDepartment of Endocrinology, Seth G S Medical College, King Edward Memorial Hospital, Parel, Mumbai, India.
Delphine DruiL'Institut du thorax, Department of Endocrinology, Centre Hospitalier Universitaire Nantes, Nantes, France.
Marta KorbonitsDepartment of Endocrinology, St Bartholomew's Hospital, London, UK; London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Maralyn R DruceDepartment of Endocrinology, St Bartholomew's Hospital, London, UK; London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Caroline BrainDivision of Endocrine Surgery, University College Hospital and Great Ormond Street Hospital, London, United Kingdom.
Tom KurzawinskiDivision of Endocrine Surgery, University College Hospital and Great Ormond Street Hospital, London, United Kingdom.
Atila PatocsHungarian Academy of Sciences and Semmelweis University, HSA-SE "Lendület" Hereditary Endocrine Tumour Research Group, Budapest, Hungary.
Maria Joao BugalhoServiço de Endocrinologia, Diabetes e Metabolismo, Centro Hospitalar Universitário Lisboa Norte-Hospital Santa Maria, Lisboa, Portugal; Centro Académico de Medicina de Lisboa, Universidade Lisboa, Lisboa, Portugal.
Andre LacroixEndocrine Division, Department of Medicine, Centre Hospitalier de l'Universite í de Montréal, Montreal, QC, Canada.
Philippe CaronCentre Hospitalier Universitaire de Toulouse, Hôpital Larrey, Service d'Endocrinologie, Maladies métaboliques, Nutrition, Toulouse, France.
Patricia Fainstein-DayEndocrine and Nuclear Medicine Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Francoise Borson ChazotHospices Civils de Lyon, Fédération d'Endocrinologie, Université Claude Bernard Lyon 1, Lyon, France.
Marc KleinDepartment of Endocrinology, University Hospital, Nancy, France.
Thera P LinksDepartment of Endocrinology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
Claudio LetiziaDepartment of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy.
Laura FugazzolaDivision of Endocrine and Metabolic Diseases, Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Auxologico Italiano, University of Milan, Milan, Italy; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
Olivier ChabreCentre Hospitalier Universitaire de Grenoble, Hôpital Albert Michallon, Service d'Endocrinologie-Diabétologie-Nutrition, Grenoble, France.
Letizia CanuDepartment of Experimental and Clinical Biomedical Sciences, Endocrinology Unit, University of Florence, Florence, Italy.
Regis CohenEndocrinologie et Métabolismes, Centre Hospitalier de Saint Denis, Saint-Denis, France.
Antoine TabarinCentre Hospitalier Universitaire de Bordeaux, Hôpital du Haut Lévêque, Service d'Endocrinologie-Diabétologie et Maladies Métaboliques, Pessac, France.
Anita Spehar UroicDepartment of Pediatrics, University Hospital Centre Zagreb, Zagreb, Croatia.
Dominique MaiterService d'Endocrinologie et Nutrition, Cliniques Universitaires Saint-Luc, Universite Catholique de Louvain, Brussels, Belgium.
Sandrine LaboureauDepartment of Endocrinology, Diabetes and Nutrition, Reference Centre of Rare Thyroid Disease, Hospital of Angers, Angers, France.
Caterina MianOperative Unit of the Endocrinology, Department of Medicine, University of Padua, Padua, Italy.
Mariola PeczkowskaDepartment of Hypertension, Institute of Cardiology, Warsaw, Poland.
Frederic SebagDepartment of Endocrine Surgery, La Conception Hospital, Marseille, France.
Thierry BrueAix-Marseille Université, Institut National de la Santé et de la Recherche Médicale, Marseille Medical Genetics, Marseille, France; Assistance Publique-Hôpitaux de Marseille, Department of Endocrinology, Hôpital de la Conception, Centre de Référence des Maladies Rares de l'hypophyse, Marseille, France.
Delphine Mirebeau-PrunierDépartement de Biochimie et Génétique, Centre Hospitalier Universitaire d'Angers, Angers, France.
Laurence LeclercCentre Hospitalier Régional Universitaire de Lille, Hopital Huriez, Service d'Endocrinologie, Lille, France.
Birke BauschSection for Preventive Medicine, Department of Nephrology and General Medicine, Freiburg, Germany.
Amandine BerdelouEndocrine Oncology, Institut Gustave Roussy Ecole Doctorale de Cancerologie, Villejuif, France.
Akihiro SukuraiDepartment of Medical Genetics and Genomics, Sapporo Medical University School of Medicine, Chuo-ku, Sapporo, Hokkaido, Japan.
Petr VlcekDepartment of Nuclear Medicine and Endocrinology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Motol University Hospital, Prague, Czech Republic.
Jolanta KrajewskaDepartment of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Gliwice, Poland.
Marta BarontiniCentro de Investigaciones Endocrinológicas, "Dr César Bergadá", Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina.
Carla Vaz Ferreira VargasThyroid Section, Endocrinology Division, Hospital de Cliínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Laura ValerioDepartment of Endocrinology, University Hospital, Pisa, Italy.
Lucieli CeolinThyroid Section, Endocrinology Division, Hospital de Cliínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Srivandana AkshintalaDepartment of Pediatrics, New York University Langone Medical Center, New York, NY, USA.
Ana HoffEndocrine Genetics Unit, Endocrinology Division, Hospital das Clínicas, University of São Paulo School of Medicine, São Paulo, Brazil; Endocrine Oncology Division, Institute of Cancer of the State of São Paulo, Faculty of Medicine of the University of São Paulo, São Paulo, Brazil.
Christian GodballeDepartment of Otorhinolaryngology, Head and Neck Surgery and Audiology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Barbara JarzabDepartment of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Gliwice, Poland.
Camilo JimenezDepartment of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Charis EngGenomic Medicine Institute, Lerner Research Institute and Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Tsuneo ImaiDepartment of Breast and Endocrine Surgery, National Hospital Organization Higashinagoya National Hospital, Nagoya, Japan.
Martin SchlumbergerEndocrine Oncology, Institut Gustave Roussy Ecole Doctorale de Cancerologie, Villejuif, France.
Elizabeth GrubbsDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Henning DralleSection of Endocrine Surgery, Department of General, Visceral, and Transplantation Surgery, University Hospital Essen, Essen, Germany.
Hartmut P NeumannSection for Preventive Medicine, Department of Nephrology and General Medicine, Freiburg, Germany.
Eric BaudinEndocrine Oncology, Institut Gustave Roussy Ecole Doctorale de Cancerologie, Villejuif, France.
Institut Gustave Roussy · FRThe Maria Sklodowska-Curie National Research Institute of Oncology · PLThe University of Texas MD Anderson Cancer Center · USUniversidade Federal do Rio Grande do Sul · BRAssistance Publique Hôpitaux de Marseille · FRCentre Hospitalier Universitaire d'Angers · FRHospital General de Niños Ricardo Gutierrez · ARUniversidade de São Paulo · BRUniversity of Southern Denmark · DKAnhui Medical University · CNCentre Hospitalier de l’Université de Montréal · CACentre Hospitalier Régional et Universitaire de Nancy · FRCentre Hospitalier Saint-Denis · FRCentre Hospitalier Universitaire de Bordeaux · FRCentre Hospitalier Universitaire de Toulouse · FRCentro Hospitalar Lisboa Norte · PTCharles University · CZCleveland Clinic · USEssen University Hospital · DEGreat Ormond Street Hospital · GB

Funding

Pediatric Oncology Branch Clinical Care and EducationZIEBC011516 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GLOD, JOHN · 2013 to 2025
$69.1M
Intramural NIH HHS ZIE BC011516
6 · The paper itself

Abstract

backgroundMultiple endocrine neoplasia type 2B is a rare syndrome caused mainly by Met918Thr germline RET mutation, and characterised by medullary thyroid carcinoma, phaeochromocytoma, and extra-endocrine features. Data are scarce on the natural history of multiple endocrine neoplasia type 2B. We aimed to advance understanding of the phenotype and natural history of multiple endocrine neoplasia type 2B, to increase awareness and improve detection.

methodsThis study was a retrospective, multicentre, international study in patients carrying the Met918Thr RET variant with no age restrictions. The study was done with registry data from 48 centres globally. Data from patients followed-up from 1970 to 2016 were retrieved from May 1, 2016, to May 31, 2018. Our primary objectives were to determine overall survival, and medullary thyroid carcinoma-specific survival based on whether the patient had undergone early thyroidectomy before the age of 1 year. We also assessed remission of medullary thyroid carcinoma, incidence and treatment of phaeochromocytoma, and the penetrance of extra-endocrine features.

findings345 patients were included, of whom 338 (98%) had a thyroidectomy. 71 patients (21%) of the total cohort died at a median age of 25 years (range <1-59). Thyroidectomy was done before the age of 1 year in 20 patients, which led to long-term remission (ie, undetectable calcitonin level) in 15 (83%) of 18 individuals (2 patients died of causes unrelated to medullary thyroid carcinoma). Medullary thyroid carcinoma-specific survival curves did not show any significant difference between patients who had thyroidectomy before or after 1 year (comparison of survival curves by log-rank test: p=0·2; hazard ratio 0·35; 95% CI 0.07-1.74). However, there was a significant difference in remission status between patients who underwent thyroidectomy before and after the age of 1 year (p<0·0001). There was a significant difference in remission status between patients who underwent thyroidectomy before and after the age of 1 year (p<0·0001). In the other 318 patients who underwent thyroidectomy after 1 year of age, biochemical and structural remission was obtained in 47 (15%) of 318 individuals. Bilateral phaeochromocytoma was diagnosed in 156 (50%) of 313 patients by 28 years of age. Adrenal-sparing surgery was done in 31 patients: three (10%) of 31 patients had long-term recurrence, while normal adrenal function was obtained in 16 (62%) patients. All patients with available data (n=287) had at least one extra-endocrine feature, including 106 (56%) of 190 patients showing marfanoid body habitus, mucosal neuromas, and gastrointestinal signs.

interpretationThyroidectomy done at no later than 1 year of age is associated with a high probability of cure. The reality is that the majority of children with the syndrome will be diagnosed after this recommended age. Adrenal-sparing surgery is feasible in multiple endocrine neoplasia type 2B and affords a good chance for normal adrenal function. To improve the prognosis of such patients, it is imperative that every health-care provider be aware of the extra-endocrine signs and the natural history of this rare syndrome. The implications of this research include increasing awareness of the extra-endocrine symptoms and also recommendations for thyroidectomy before the age of 1 year.

fundingNone.

Indexed as

AdolescentAdrenal Gland NeoplasmsAdultCarcinoma, NeuroendocrineChildChild, PreschoolFemaleFollow-Up StudiesHumansInfantInternational AgenciesMaleMiddle AgedMultiple Endocrine Neoplasia Type 2bPheochromocytomaPrognosis

Identifiers

PMID30660595
PMCPMC8132299
OpenAlexW2910611591

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.